Home | Welcome to Contract Pharma   
Last Updated Thursday, May 23 2013
Print RSS Feed

Breaking News

Related Searches: Industry News •
CSL To Acquire Talecris

August 13, 2008
CSL Ltd. has signed an agreement to acquire Talecris Biotherapeutics Holdings Corp. for $3.1 billion, enhancing its position in the global plasma market. Talecris produces plasma medicines in the U.S. and operates 56 plasma collection centers and two…  Read More »
Ricerca Biosciences

August 13, 2008
Desmond Cave has been named business development director in Europe for Ricerca Biosciences. Mr. Cave will be based in the UK and will focus on selling Ricerca’s discovery and preclinical services to the pharmaceutical and biotechnology industr…  Read More »
AAIPharma

August 13, 2008
Ronald Kershner has been appointed to lead AAIPharma's North American Biostatistics and Data Management Services groups. Mr. Kershner has more than 25 years of industry experience at several large pharmaceutical, biotechnology and contract research c…  Read More »
Schering-Plough Establishes Shanghai Operation

August 12, 2008
Schering-Plough has expanded its presence in China by establishing Shanghai Schering-Plough Pharmaceutical Co. Ltd. A wholly-owned operation based in Shanghai, the unit was formed through the acquisition of shares of its former joint venture partners…  Read More »
DSM To Manufacture Antibody for MorphoSys

August 12, 2008
DSM Biologics and MorphoSys AG signed a biopharmaceutical manufacturing agreement covering process development and cGMP manufacturing of MOR202, a fully human HuCAL antibody being studied for the treatment of multiple myeloma. DSM will manufacture MO…  Read More »
UCB Outsources Med-Chem Program to BioFocus DPI

August 12, 2008
BioFocus DPI, Galapagos' service division, has signed a contract with UCB to supply chemistry services in the UK for one of UCB's medicinal chemistry programs. The total contract value for Galapagos could potentially exceed $6 million. Galapagos is a…  Read More »
Enzon May Sell Specialty Pharma Unit

August 11, 2008
Enzon Pharmaceuticals is exploring strategic options for its specialty pharmaceuticals business. These options include selling the entire specialty business or selling one or more of Enzon's marketed products, Oncaspar, DepoCyt, Abelcet and Adagen, a…  Read More »
Alnylam, Planck Institute To Study RNAi

August 11, 2008
Alnylam Pharmaceuticals has formed an exclusive research agreement with the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany, to investigate the molecular mechanisms of small interfering RNA (siRNA), the molecules that…  Read More »
Merck Suspends Trial for I-vation TA

August 11, 2008
Merck is reevaluating the design of its Phase IIb trial for I-vation TA that it's conducting with SurModics, Inc. and therefore suspending enrollment of new patients in the trial. The decision follows recent study results comparing laser treatment an…  Read More »
Michael Mallon has been appointed business development manager, DPT Laboratories.

August 8, 2008
Michael Mallon has been appointed business development manager, DPT Laboratories. Mr. Mallon was most recently with Catalent Pharma Solutions, where he was responsible for managing selected accounts in the northeastern U.S. The contract service portf…  Read More »
CMC Biologics, Symphogen Enter Manufacturing Pact

August 8, 2008
CMC Biologics has entered into an agreement with Symphogen for process development and cGMP manufacture of an undisclosed polyclonal antibody product candidate from Symphogen’s development pipeline. Terms of the agreement were not disclosed. &…  Read More »
FDA Delays Centocor's BLA for Psoriasis Drug

August 8, 2008
Centocor's BLA for ustekinumab for the treatment of plaque psoriasis has been delayed by three months to December 2008. Centocor filed the BLA late in 2007.     The FDA extended the review period in order to review amendments to the…  Read More »
Valeant, Meda Form JV

August 7, 2008
Valeant Pharmaceuticals and Meda AB have agreed to form joint ventures in Australia, Canada and Mexico to develop, market and commercialize certain current and future products. The joint ventures will be majority-owned by Meda; Valeant will own a min…  Read More »
Financial Report: Parexel FY08

August 7, 2008
Parexel 4Q Revenues: $331.9 million (+31%) 4Q Earnings: $25.0 million (+140%) FY Revenues: $1.2 billion (+27%) FY Earnings: $64.6 million (+73%) Comments: Record quarterly and FY service revenue was $272.2 million (+33%) and $964.3 mil…  Read More »
Penn Pharmaceutical Services

August 7, 2008
Dr. Sue Price has been appointed head of Clinical Trial Supplies (CTS), Penn Pharmaceutical Services. Dr. Price has experience working with major pharmaceutical companies including Sanofi-Winthrop and Brecon Pharmaceuticals. Most recently she has wor…  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:

Follow Contract Pharma On
Please visit our sister sites: